Sol-Gel Technologies Ltd.

Please note: The information displayed on this page might be outdated.
Sol-Gel Technologies Ltd.: Clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel has two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has the potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea with PDUFA date on April 26th. Twyneo has the potential to be the first acne treatment that contains a fixed dose combination of BPO and tretinoin with PDUFA date on August 1st. Additional branded pipeline assets include SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctuate palmoplantar keratoderma, and PC assets tapinarof and roflumilast. Sol-Gel has revenue from several generic collaborations; it was also informed by its collaboration partner that the launch of an additional FDA-approved generic drug is expected in 2Q21. Annual sales of the brand name product exceeded $180 million in the US in 2019.
Based in...
Asia, Israel
Clinical Stage
Registration Stage
Disease Space
Autoimmune, Dermatology
Pre-Revenues, Revenues
Investment Strategy
Under the Radar
Public, USA
Market Cap
Therapeutic Modalities
Platform Technology
Sol-Gel Technologies Ltd
7 Golda Meir St.
Ness Ziona, HaMerkaz 7403650

Company Participants at Sol-Gel Analyst & Investor Day 2019 in NYC

  • Alon Seri-Levy, PhD, CEO/Co-Founder
  • Gilad Mamlok, Chief Financial Officer
  • John Vieira, US Head of Commercialization

Top 10 Holders of Sol-Gel Technologies Ltd.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Phoenix Holdings Ltd. 10.02 2,574,922 0.00 13F 3/31/23
Armistice Capital LLC 9.37 2,408,000 0.00 13F 3/31/23
Migdal Insurance & Financial Holdings Ltd. 4.79 1,230,636 0.00 13F 3/31/23
Harel Insurance Investments & Financial Services Ltd. 3.58 920,333 0.00 13F 3/31/23
Kingdon Capital Management LLC 3.00 770,965 0.00 13F 3/31/23
Meitav Mutual Funds Ltd. 2.36 606,445 0.00 Funds 3/30/23
Yelin Lapidot Mutual Fund Management Ltd. 0.89 229,178 0.00 Funds 3/30/23
Raymond James Financial Services, Inc. 0.23 59,006 0.00 13F 3/31/23
Raymond James & Associates, Inc. 0.14 36,582 0.00 13F 3/31/23
Raymond James & Associates, Inc. (Invt Mgmt) 0.11 24,418 0.00 Funds 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.